期刊文献+

氟伐他汀辅助治疗慢性阻塞性肺疾病并发肺动脉高压56例 被引量:6

下载PDF
导出
摘要 目的探讨氟伐他汀对慢性阻塞性肺疾病并发肺动脉高压患者的治疗效果。方法慢性阻塞性肺疾病并发肺动脉高压患者112例,随机分为对照组和治疗组各56例,分别给予安慰药(同样剂型的淀粉)或者氟伐他汀口服,剂量为40 mg·d-1,为期6个月。比较两组患者治疗前后的血流动力学、生化指标、治疗效果等。结果①治疗组的血脂4项水平与治疗前和对照组治疗后的水平有差异,且除了高密度脂蛋白胆固醇(HDL-C)升高外,其余均降低;②治疗组的运动耐力时间均长于治疗前和对照组治疗后的水平(P<0.05),肺动脉收缩压低于对照组[分别为(42.3±5.7),(47.2±6.9)mmHg](P<0.05),且博格呼吸困难评分低于对照组。结论氟伐他汀可显著改善慢性阻塞性肺疾病并发肺动脉高压患者的肺动脉高压和呼吸困难症状,增强患者的运动耐受,可应用于该疾病的临床治疗。
作者 王巍 林建青
出处 《医药导报》 CAS 北大核心 2012年第9期1163-1165,共3页 Herald of Medicine
  • 相关文献

参考文献15

  • 1ZULLI R, DONATI P, NICOSIA F, et al. Increased QT dispersion:a negative prognostic finding in chronic obstructive pulmonary disease[ J ]. Int Emerg Med, 2006,1 (4) : 279- 286.
  • 2COOPER R, GHALI J, SIMMONS B E, et al. Elevated pulmonary artery pressure, an independent predictor of mortality[J]. Chest,1991,99(1) :112-120.
  • 3WEITZENBLUM E, KESSLER R, OSWALD M, et al. Medical treatment of pulmonary hypertension in chronic lung disease [J]. Eur Respir J, 1994,7 ( 1 ) : 148-152.
  • 4陈汇.他汀类药物抗动脉粥样硬化研究进展[J].医药导报,2007,26(4):331-334. 被引量:12
  • 5CORTE T J, WORTS J. Role of pravastatin in pulmonary hypertension in chronic obstructive pulmonary disease [ J ]. Clin Sci ( Lond), 2009,116 ( 6 ) : 493 -495.
  • 6WILSON R C,JONES P W. A comparison of the visual analogue scale and modified Borg scale for the measurement of dyspnoea during exercise [ J ]. Clin Sci ( Lond), 1989,76 (3) :277-282.
  • 7廖亚玲,安薇,张维.玉屏风散辅助治疗稳定期慢性阻塞性肺疾病30例[J].医药导报,2011,30(1):63-66. 被引量:13
  • 8BALKISSOON R, LOMMATZSCH S, CAROLAN B, et al. Chronic obstructive pulmonary disease: a concise review [J]. Med Clin North Am,2011,95(6) :1125-1141.
  • 9BURGER C D. Pulmonary hypertension in COPD:a review and consideration of the role of arterial vasodilators [ J ]. COPD, 2009,6 ( 2 ) : 137-144.
  • 10黄赛杰.他汀类药物的非降脂作用[J].医药导报,2006,25(1):25-27. 被引量:5

二级参考文献46

  • 1洪广祥.中医药治疗慢性阻塞性肺疾病的几点思考[J].中华中医药杂志,2005,20(1):16-19. 被引量:95
  • 2张伟,李刚,张心月,邵雨萌.从痰、瘀、虚辨治慢性阻塞性肺疾病[J].中医药信息,2006,23(5):6-8. 被引量:26
  • 3毕玉霞,刘诗柱.玉屏风散对小白鼠免疫功能影响的实验研究[J].中兽医医药杂志,2007,26(1):31-33. 被引量:17
  • 4Maeda T, Matsunuma A, Kawane T, et al. Simvastatin promotes osteoblast differentiation and mineralization in MC3 T3-EI cells[J].Biochem Biophys Res Commun,2001,280(3):874 - 879.
  • 5Mundy G, Garrett R, Harris S, et al. Stimulation of bone formation in vitro and in rodents by statins [ J ]. Science, 1999,286(5446):1946 - 1951.
  • 6Meier C R, Schlienger R G, Kraenzlin M E, et al. HMG-CoA reductase inhibitors and the risk of fractures[ J ]. JAMA ,2000,283(17):3205-3210.
  • 7Wang P S, Solomon D H, Mogun H, et al. HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients [ J ]. JAMA,2000,283(17): 3211 - 3216.
  • 8Undas A, Brummel K E, Musial J ,et al. Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, factor and by enhancing factor V a inactivation [ J ]. Circulation, 2001,103(18):2248-2253.
  • 9Gertz K, Laufs U, Lindauer U, et al. Withdrawal of statin treatment abrogates stroke otection in mice[J]. Stroke,2003,34(3):551-557.
  • 10Eto M, Kozai T, Cosentino F, et al. Statin prevents tissue factor expression in human endothelial cells: role of Rho/Rho2 kinase and Akt pathways[ J ]. Circulation ,2002,105(15): 1756 - 1759.

共引文献27

同被引文献56

引证文献6

二级引证文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部